BRD4 and neoplasm: Moreover, a combined therapy using cRGD-modified nanoparticles (cRGD-P) co-delivering doxorubicin (DOX) and BRD4 PROTAC degrader ARV-825 showed synergistic tumor inhibition and a better efficacy than the individual administration of these compounds [181].